$52.3 B

BSX Mkt cap, 20-Sep-2018

$4.9 B

Boston Scientific Corporation Revenue Q2, 2018
Boston Scientific Corporation Gross profit (Q2, 2018)3.5 B
Boston Scientific Corporation Gross profit margin (Q2, 2018), %71%
Boston Scientific Corporation Net income (Q2, 2018)853 M
Boston Scientific Corporation EBIT (Q2, 2018)799 M
Boston Scientific Corporation Cash, 30-Jun-2018208 M
Boston Scientific Corporation EV56.9 B

Boston Scientific Corporation Revenue

Boston Scientific Corporation revenue was $8.39 b in FY, 2016 which is a 12.2% year over year increase from the previous period.

Embed Graph

Boston Scientific Corporation Revenue Breakdown

Embed Graph

Boston Scientific Corporation revenue breakdown by business segment: 35.3% from MedSurg, 24.8% from Rhythm Management and 39.9% from Cardiovascular

Boston Scientific Corporation Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

7.1 b7.4 b7.5 b8.4 b

Revenue growth, %

3%1%12%

Cost of goods sold

2.2 b2.2 b2.2 b2.4 b

Gross profit

5 b5.2 b5.3 b6 b

Gross profit Margin, %

70%70%71%71%

EBIT

120 m(301 m)(327 m)447 m

EBIT margin, %

2%(4%)(4%)5%

Interest expense

324 m216 m284 m233 m

Pre tax profit

(223 m)(509 m)(650 m)177 m

Income tax expense

(102 m)(390 m)(411 m)(170 m)

Net Income

(121 m)(119 m)(239 m)347 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

1.7 b1.8 b1.9 b1.8 b1.8 b1.8 b1.9 b2 b2.1 b2.1 b2.2 b2.3 b2.4 b4.9 b

Cost of goods sold

510 m537 m563 m550 m520 m540 m539 m573 m639 m594 m650 m632 m672 m1.4 b

Gross profit

1.2 b1.2 b1.3 b1.3 b1.2 b1.3 b1.3 b1.4 b1.5 b1.5 b1.5 b1.6 b1.7 b3.5 b

Gross profit Margin, %

71%70%70%70%71%71%71%71%70%72%70%72%72%71%

R&D expense

217 m191 m206 m212 m192 m220 m221 m210 m222 m232 m235 m244 m261 m536 m

General and administrative expense

658 m666 m743 m741 m668 m700 m729 m716 m779 m772 m794 m815 m860 m1.7 b

Operating expense total

875 m857 m949 m953 m860 m920 m950 m926 m1 b1 b1 b1.1 b1.1 b2.3 b

Depreciation and amortization

141 m288 m

EBIT

103 m197 m(69 m)64 m24 m219 m(299 m)293 m(334 m)348 m364 m225 m407 m799 m

EBIT margin, %

6%11%(4%)3%1%12%(16%)15%(16%)17%17%10%17%16%

Interest expense

137 m54 m53 m54 m60 m106 m58 m59 m59 m58 m57 m58 m61 m119 m

Pre tax profit

(40 m)146 m(104 m)3 m(51 m)105 m(367 m)228 m(397 m)257 m305 m91 m323 m670 m

Income tax expense

(35 m)13 m(108 m)(40 m)(50 m)3 m(169 m)26 m(190 m)29 m15 m(55 m)26 m(183 m)

Net Income

(5 m)133 m4 m43 m(1 m)102 m(198 m)202 m(207 m)228 m290 m146 m298 m853 m

Boston Scientific Corporation Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

217 m587 m319 m196 m

Inventories

897 m946 m1 b955 m

Current Assets

3 b3.6 b3.5 b3.2 b

PP&E

1.5 b1.5 b1.5 b1.6 b

Goodwill

5.7 b5.9 b6.5 b6.7 b

Total Assets

16.6 b17 b18.1 b18.1 b

Accounts Payable

246 m262 m209 m447 m

Current Liabilities

1.8 b2.8 b2.4 b3.6 b

Long-term debt

4.2 b3.9 b5.7 b5.4 b

Total Debt

4.2 b3.9 b5.7 b5.4 b

Additional Paid-in Capital

16.6 b16.7 b16.9 b17 b

Retained Earnings

(8.6 b)(8.7 b)(8.9 b)(8.6 b)

Total Equity

6.5 b6.5 b6.3 b6.7 b

Debt to Equity Ratio

0.6 x0.6 x0.9 x0.8 x

Debt to Assets Ratio

0.3 x0.2 x0.3 x0.3 x

Financial Leverage

2.5 x2.6 x2.9 x2.7 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

571 m191 m357 m246 m242 m903 m350 m338 m438 m237 m156 m195 m287 m208 m

Accounts Receivable

1.2 b1.2 b1.3 b1.2 b1.2 b1.2 b1.3 b1.3 b1.4 b1.4 b1.4 b1.4 b1.6 b1.6 b

Inventories

895 m926 m949 m989 m958 m968 m1.1 b1 b981 m998 m971 m1 b1.1 b1.1 b

Current Assets

3.5 b2.9 b3.2 b3.2 b3.2 b3.8 b3.5 b3.2 b3.3 b3.2 b3 b3.2 b4.1 b3.9 b

PP&E

1.5 b1.5 b1.5 b1.5 b1.5 b1.5 b1.5 b1.5 b1.5 b1.5 b1.7 b1.7 b1.7 b1.7 b

Goodwill

5.6 b5.7 b5.7 b5.9 b5.9 b5.9 b6.5 b6.5 b6.5 b6.5 b6.7 b6.9 b7 b7.2 b

Total Assets

16.9 b16.3 b16.5 b16.7 b16.5 b17.1 b18.2 b17.7 b17.8 b17.7 b17.9 b18.4 b19.2 b19.6 b

Accounts Payable

238 m241 m241 m234 m228 m191 m210 m232 m284 m298 m376 m376 m404 m403 m

Current Liabilities

1.9 b1.7 b1.8 b1.8 b2.5 b1.9 b2.2 b2.6 b3.2 b3 b3.5 b4.3 b5 b4.8 b

Long-term debt

4.2 b4.2 b4.3 b4.2 b3.8 b5.1 b5.8 b5.4 b5.2 b5.2 b5.5 b4.8 b4.8 b4.8 b

Total Debt

4.2 b4.2 b4.3 b4.2 b3.8 b5.1 b5.8 b5.4 b5.2 b5.2 b5.5 b4.8 b4.8 b4.8 b

Additional Paid-in Capital

16.5 b16.6 b16.6 b16.7 b16.8 b16.8 b16.8 b16.8 b16.9 b17 b17 b17.1 b17.2 b17.2 b

Retained Earnings

(8.7 b)(8.4 b)(8.4 b)(8.4 b)(8.7 b)(8.6 b)(8.8 b)(8.7 b)(8.9 b)(8.7 b)(8.2 b)(8.1 b)(8.3 b)(7.8 b)

Total Equity

6.6 b6.4 b6.5 b6.2 b6.5 b7.1 b7.2 b7 b7.7 b

Financial Leverage

2.6 x2.8 x2.7 x2.9 x2.7 x2.5 x2.5 x2.7 x2.5 x

Boston Scientific Corporation Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(121 m)(119 m)(239 m)347 m

Accounts Receivable

(101 m)53 m(17 m)(216 m)

Inventories

(7 m)(81 m)3 m40 m

Accounts Payable

(37 m)620 m(20 m)553 m

Cash From Operating Activities

1.1 b1.3 b600 m972 m

Purchases of PP&E

(245 m)(259 m)(247 m)(376 m)

Interest Paid

329 m221 m283 m233 m

Income Taxes Paid

67 m74 m80 m94 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Net Income

(5 m)133 m4 m43 m(1 m)

Boston Scientific Corporation Ratios

USDY, 2018

EV/EBIT

71.2 x

Financial Leverage

2.5 x
Report incorrect company information

Boston Scientific Corporation Operating Metrics

Boston Scientific Corporation's Customers was reported to be 35 k in FY, 2016.
FY, 2016

Countries

120

Customers

35 k

Facilities

13
Report incorrect company information